We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lifts Clinical Hold on Oxygen Biotherapeutics’ Oxycyte
FDA Lifts Clinical Hold on Oxygen Biotherapeutics’ Oxycyte
After six years of uncertainty, the FDA has lifted a clinical hold on trials of Oxygen Biotherapeutics’ Oxycyte intravenous emulsion, reviving hope for the drugmaker’s traumatic brain injury treatment.